I combined a respiratory stimulant and an opioid. The stimulant counteracts the effect of respiratory depression caused by opioids.  The drug is fast-tracked for FDA 505(b)2 approval.  The target market is the 137 million prescriptions of Vicodin written yearly. At $200 per prescription the market is $27 billion. My patent covers the respiratory stimulant combined with 14 other opioids, benzodiazepines, and barbiturates.